Sinopharm's COVID-19 Vaccine Demonstrates 79% Efficacy in P-III Study
Shots:
- The results of an interim analysis of P-III study showed that the safety of the new coronavirus inactivated vaccine after inoculation
- All patients produced high-titer Abs- the neutralizing Ab positive conversion rate was 99.52% while vaccine efficacy was 79.34%
- The vaccine has been granted authorization in several countries and has also been rolled out in part in China. The company is now seeking full approval in China
Ref: Sinopharm | Image: Sinopharm
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com